Descreva o achado como no laudo. A resposta aponta uma das categorias publicadas, com a probabilidade e o trecho que a decide.
Categorias
Reescritas a partir da fonte e citadas
Nonviable
1 de 4
LR-TR Nonviable
Treated observation showing no perceived intralesional enhancement, or showing only expected post-treatment enhancement patterns (e.g., a thin uniform peripheral rim of enhancement) for the type of locoregional therapy used and the time elapsed since treatment. This category indicates no imaging evidence of gross (macroscopic) tumor viability, though it does not exclude microscopic tumor on histology.
CondutaPer the AASLD/LI-RADS consensus management suggestions cited in the source, a nonviable treated observation is managed with continued routine imaging surveillance; no measurement of viable tumor is reported.
RiscoReflects low perceived probability of macroscopic tumor viability/recurrence.
Treated observation with enhancement that cannot be confidently categorized as either viable or nonviable because of overlapping post-treatment enhancement features, in the absence of technical or patient-related limitations (i.e., the study is adequate but findings are indeterminate).
CondutaSource notes that for an equivocal response the decision to re-treat is weighed against short-interval follow-up imaging, typically after multidisciplinary discussion; if unsure between categories the algorithm directs choosing Equivocal. The viable-tumor size is still reported.
RiscoIntermediate / uncertain probability of residual or recurrent viable tumor.
Treated observation with nodular, mass-like, or thick irregular tissue showing arterial-phase hyperenhancement (APHE), 'washout' appearance, or enhancement similar to the pre-treatment tumor. These features indicate macroscopic viable tumor with high certainty (applies to all locoregional therapies except radiation-based therapy, where intralesional enhancement and washout can persist for months before regressing).
CondutaPer the source, the largest single dimension of the enhancing (viable) tumor is measured and reported to guide re-treatment or alternative therapy; reporting the pre- and post-treatment category/size communicates magnitude of response and transplant/downstaging eligibility.
RiscoReflects high perceived probability of residual/recurrent viable tumor.
Treated observation in which treatment response cannot be assessed because of image degradation or omission — e.g., inadequate or absent multiphase post-contrast imaging, motion or other technical artifact, or missing pre-treatment comparison. The study quality, not the lesion biology, precludes assigning a viability category.
CondutaPer the source algorithm, a nonevaluable observation should be re-imaged after the technical limitation is corrected (repeat or optimized contrast-enhanced CT/MRI) so that a definitive LR-TR category can be assigned; no viable-tumor measurement is reported until evaluable.
RiscoNo viability probability can be assigned — the category conveys uncertainty due to inadequate technique rather than a level of tumor-viability risk.
verificadoLI-RADS Treatment Response algorithm (CT/MRI)PMC6920285 (Kierans/Chernyak et al., Insights Imaging 2019) 'LR-TR response categories - LR-TR Nonevaluable' (treatment response cannot be evaluated due to image degradation/omission); corroborated by PMC5771991 (Mendiratta-Lala et al., Abdom Radiol 2017) 'LI-RADS treatment response algorithm'.